Keyword: Johnson & Johnson
With a new JAMA study, Johnson & Johnson just got some new ammo for its defense against lawsuits claiming its talc products caused ovarian cancer.
J&J has mostly opted to fight its talc battles in court rather than settle. But this week, the drugmaker inked a $2 million deal with one plaintiff.
With a nod in heart failure patients already secured, AstraZeneca's Farxiga has now landed a priority review in patients with or without diabetes.
We may be focusing on our forecasts for the year ahead with today's issue, but here's some Friday news we thought you shouldn't miss.
Johnson & Johnson faces around 16,800 talc cases, but it just scored its latest win in a Los Angeles court.
Xtandi is ready to take on its familiar foe with a new green light in metastatic, castration-sensitive prostate cancer
Brukinsa came up short in a head-to-head tilt with Imbruvica, failing to outdo the blockbuster at producing complete and very good partial responses.
There's a lot at stake in the world of pharma litigation, and in two cases involving J&J and Gilead, attorney misconduct allegations have come up.
AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung execs.
J&J chief Alex Gorsky has assured plenty of critics that its talc products are safe, but he's not interested in explaining to Congress.